Effects of combined gonadotropin-releasing hormone agonist and growth hormone therapy on adult height in precocious puberty: a further contribution.

Pucarelli I, Segni M, Ortore M, Arcadi E, Pasquino AM

Journal of pediatric endocrinology & metabolism : JPEM1 Sept 2003Cited by 36 (Europe PMC)

PMID14513877DOI10.1515/jpem.2003.16.7.1005PepBankPUB-14513877

Publisher page PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study6

2 results from studies that gave the peptide. 2 results from people.

01HumanNon-randomized trialEfficacy outcome
In girls with central precocious puberty, adult height with triptorelin alone did not significantly exceed pretreatment predictions from accelerated-girl tables.
In plain wordsIn girls with precocious puberty, adult height with triptorelin alone did not significantly exceed the pretreatment prediction from accelerated-girl tables.
Peptide
Triptorelin (Trelstar, Decapeptyl)
Outcome
No significant changeAdult height versus accelerated-girl prediction
Study
n = 18
Comparator
Pretreatment predicted adult height using accelerated-girl tables
Outcome group
Linear growth · Endocrine and hormones
Studied dose
100 microg/kg every 21 days · intramuscular · at least 2-3 yearsAs given in this study (human).
Measurements
Adult height
156.6 cm
GnRHa alone
Predicted adult height
153.9 cm
accelerated-girl tables
Source sentences
Summary
The adult height of the GnRH alone treated group (156.6 +/- 5.7) was not significantly higher than pre-treatment PAH if calculated on Bayley and Pinneau tables for accelerated girls (153.9 +/- 3.8 cm), whilst it remained significantly higher if calculated on tables for average girls (149.6 +/- 4.0 cm) (p < 0.001).
1 context sentence(design, population, supporting numbers)
Summary · context
The other 18, matched for bone age (BA), CA and duration of GnRHa treatment, who showed the same growth pattern but refused GH treatment, remained on GnRHa alone, and were used as a control group to evaluate GH efficacy.
Report a problemFND-1451387704
02HumanNon-randomized trialEfficacy outcome
In girls with central precocious puberty, adult height with triptorelin alone significantly exceeded pretreatment predictions from average-girl tables.
In plain wordsIn girls with precocious puberty, adult height with triptorelin alone exceeded the pretreatment prediction from average-girl tables.
Peptide
Triptorelin (Trelstar, Decapeptyl)
Outcome
IncreaseAdult height versus average-girl prediction
Study
n = 18
Comparator
Pretreatment predicted adult height using average-girl tables
Outcome group
Linear growth · Endocrine and hormones
Studied dose
100 microg/kg every 21 days · intramuscular · at least 2-3 yearsAs given in this study (human).
Measurements
Adult height
156.6 cm
GnRHa alone
Predicted adult height
149.6 cm
average-girl tables
Source sentences
Summary
The adult height of the GnRH alone treated group (156.6 +/- 5.7) was not significantly higher than pre-treatment PAH if calculated on Bayley and Pinneau tables for accelerated girls (153.9 +/- 3.8 cm), whilst it remained significantly higher if calculated on tables for average girls (149.6 +/- 4.0 cm) (p < 0.001).
1 context sentence(design, population, supporting numbers)
Summary · context
The other 18, matched for bone age (BA), CA and duration of GnRHa treatment, who showed the same growth pattern but refused GH treatment, remained on GnRHa alone, and were used as a control group to evaluate GH efficacy.
Report a problemFND-1451387705

Studies that did not test the peptide alone4

In this study, Triptorelin (Trelstar, Decapeptyl) was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Triptorelin (Trelstar, Decapeptyl).

03HumanNot a test of Triptorelin (Trelstar, Decapeptyl) aloneNon-randomized trialEfficacy outcome
In girls with central precocious puberty, GH plus triptorelin produced greater height gain over accelerated-girl predictions than triptorelin alone.
In plain wordsIn girls with precocious puberty, GH plus triptorelin produced greater height gain over accelerated-girl predictions than triptorelin alone.
Peptide
Triptorelin (Trelstar, Decapeptyl)
Outcome
IncreaseHeight gain versus accelerated-girl prediction
Study
n = 35
Comparator
Triptorelin alone
Outcome group
Linear growth · Endocrine and hormones
Measurements
Height gain
8.2 cm
GH plus GnRHa accelerated-girl tables
Height gain
2.3 cm
GnRHa alone accelerated-girl tables
Source sentences
Summary
The gain between pre-treatment PAH and final height was 8.2 +/- 4.8 cm according to tables for accelerated girls and 12.7 +/- 4.8 cm according to tables for average girls in patients treated with GH plus GnRHa; while in patients treated with GnRH alone the gain calculated between pre-treatment PAH f…
3 context sentences(design, population, supporting numbers)
Summary · context
while in patients treated with GnRH alone the gain calculated between pre-treatment PAH for accelerated girls was just 2.3 +/- 2.9 cm and 7.1 +/- 2.7 cm greater than pre-treatment PAH for average girls.
Summary · context
The difference between the gain obtained in the two groups (about 6 cm) remained the same, however PAH was calculated.
Summary · context
The other 18, matched for bone age (BA), CA and duration of GnRHa treatment, who showed the same growth pattern but refused GH treatment, remained on GnRHa alone, and were used as a control group to evaluate GH efficacy.
In this study, Triptorelin (Trelstar, Decapeptyl) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Triptorelin (Trelstar, Decapeptyl).
Report a problemFND-1451387706
04HumanNot a test of Triptorelin (Trelstar, Decapeptyl) aloneNon-randomized trialEfficacy outcome
In girls with central precocious puberty, GH plus triptorelin produced greater height gain over average-girl predictions than triptorelin alone.
In plain wordsIn girls with precocious puberty, GH plus triptorelin produced greater height gain over average-girl predictions than triptorelin alone.
Peptide
Triptorelin (Trelstar, Decapeptyl)
Outcome
IncreaseHeight gain versus average-girl prediction
Study
n = 35
Comparator
Triptorelin alone
Outcome group
Linear growth · Endocrine and hormones
Measurements
Height gain
12.7 cm
GH plus GnRHa average-girl tables
Height gain
7.1 cm
GnRHa alone average-girl tables
Source sentences
Summary
The gain between pre-treatment PAH and final height was 8.2 +/- 4.8 cm according to tables for accelerated girls and 12.7 +/- 4.8 cm according to tables for average girls in patients treated with GH plus GnRHa; while in patients treated with GnRH alone the gain calculated between pre-treatment PAH f…
3 context sentences(design, population, supporting numbers)
Summary · context
while in patients treated with GnRH alone the gain calculated between pre-treatment PAH for accelerated girls was just 2.3 +/- 2.9 cm and 7.1 +/- 2.7 cm greater than pre-treatment PAH for average girls.
Summary · context
The difference between the gain obtained in the two groups (about 6 cm) remained the same, however PAH was calculated.
Summary · context
The other 18, matched for bone age (BA), CA and duration of GnRHa treatment, who showed the same growth pattern but refused GH treatment, remained on GnRHa alone, and were used as a control group to evaluate GH efficacy.
In this study, Triptorelin (Trelstar, Decapeptyl) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Triptorelin (Trelstar, Decapeptyl).
Report a problemFND-1451387707
05HumanNot a test of Triptorelin (Trelstar, Decapeptyl) aloneNon-randomized trialEfficacy outcome
In girls with central precocious puberty, adult height with GH plus triptorelin exceeded pretreatment predictions from accelerated-girl tables.
In plain wordsIn girls with precocious puberty, adult height with GH plus triptorelin exceeded the pretreatment prediction from accelerated-girl tables.
Peptide
Triptorelin (Trelstar, Decapeptyl)
Outcome
IncreaseAdult height versus accelerated-girl prediction
Study
n = 17
Comparator
Pretreatment predicted adult height using accelerated-girl tables
Outcome group
Linear growth · Endocrine and hormones
Measurements
Adult height
161.2 cm
GH plus GnRHa
Predicted adult height
153.2 cm
accelerated-girl tables
Source sentences
Summary
Patients of the group treated with GH plus GnRHa showed an adult height (161.2 +/- 4.8 cm) significantly higher (p < 0.001) than pre-treatment predicted adult height (PAH) calculated according to tables either for accelerated girls (153.2 +/- 5.0 cm) or for average girls (148.6 +/- 4.3 cm).
1 context sentence(design, population, supporting numbers)
Summary · context
The other 18, matched for bone age (BA), CA and duration of GnRHa treatment, who showed the same growth pattern but refused GH treatment, remained on GnRHa alone, and were used as a control group to evaluate GH efficacy.
In this study, Triptorelin (Trelstar, Decapeptyl) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Triptorelin (Trelstar, Decapeptyl).
Report a problemFND-1451387702
06HumanNot a test of Triptorelin (Trelstar, Decapeptyl) aloneNon-randomized trialEfficacy outcome
In girls with central precocious puberty, adult height with GH plus triptorelin exceeded pretreatment predictions from average-girl tables.
In plain wordsIn girls with precocious puberty, adult height with GH plus triptorelin exceeded the pretreatment prediction from average-girl tables.
Peptide
Triptorelin (Trelstar, Decapeptyl)
Outcome
IncreaseAdult height versus average-girl prediction
Study
n = 17
Comparator
Pretreatment predicted adult height using average-girl tables
Outcome group
Linear growth · Endocrine and hormones
Measurements
Adult height
161.2 cm
GH plus GnRHa
Predicted adult height
148.6 cm
average-girl tables
Source sentences
Summary
Patients of the group treated with GH plus GnRHa showed an adult height (161.2 +/- 4.8 cm) significantly higher (p < 0.001) than pre-treatment predicted adult height (PAH) calculated according to tables either for accelerated girls (153.2 +/- 5.0 cm) or for average girls (148.6 +/- 4.3 cm).
1 context sentence(design, population, supporting numbers)
Summary · context
The other 18, matched for bone age (BA), CA and duration of GnRHa treatment, who showed the same growth pattern but refused GH treatment, remained on GnRHa alone, and were used as a control group to evaluate GH efficacy.
In this study, Triptorelin (Trelstar, Decapeptyl) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Triptorelin (Trelstar, Decapeptyl).
Report a problemFND-1451387703

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
22 Oct 2026, 02:26 UTC
Study results updated
Version 1
21 Oct 2026, 18:59 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

MeSH terms

PepBank is a research reference. Talk to a doctor before you use any peptide.